drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti‑SLAMF7); biologic
drug_description
Intravenous anti‑SLAMF7 monoclonal antibody that activates NK cells and mediates ADCC against SLAMF7‑positive myeloma cells.
nci_thesaurus_concept_id
C66982
nci_thesaurus_preferred_term
Elotuzumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.
drug_mesh_term
elotuzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
General immune activator
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti‑SLAMF7 (CS1) IgG1 monoclonal antibody that binds SLAMF7 on myeloma and NK cells, activates NK cells, and mediates Fc‑dependent antibody‑dependent cellular cytotoxicity (ADCC) to eliminate SLAMF7‑positive myeloma cells.
drug_name
Elotuzumab
nct_id_drug_ref
NCT06208150